EGCG’s anticancer potential unveiled: triggering apoptosis in lung cancer cell lines through in vitro investigation
PeerJ · 26.03.2025 · 13 · e19135
DOI: 10.7717/peerj.19135 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, online erschienen am 26.03.2025. Verfasst von Al Moutassem Billah Khair und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical & Dental Sciences, College of Dentistry, Ajman University, Ajman, United Arab Emirates. Hauptthemen laut MEDLINE: Catechin, Apoptosis, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ajman University Internal Research.
Abstract (Originalsprache)
Background
Novel treatment techniques are needed since lung cancer is still a major worldwide health concern. Green tea contains a component called epigallocatechin-3-gallate (EGCG), which has demonstrated potential anticancer properties. This work sought to understand how EGCG affects the phosphatidylinositol-3-kinase protein kinase B (PI3K/Akt) signaling pathway, which in turn causes apoptosis in H1299 lung cancer cells.
Methods
In this experiment, multiple dosages of EGCG were applied to five H1299 cells and five A549 cell lines for a duration of 72 h. Apoptotic pathways, cellular responses, and protein expression levels were investigated in relation to EGCG by morphological, biochemical, and proliferation/migration investigations.
Results
In H1299 and A549 cells, EGCG raised apoptosis rates and, in a dose-dependent way, hindered cell growth. The levels of phosphorylated Akt (p-Akt) and PI3K (p-PI3K) dramatically reduced following EGCG administration, despite no significant alterations in Akt and PI3K expressions. These results imply that EGCG inhibits the activation of the PI3K/Akt signaling pathway, which in turn causes apoptosis in H1299 and A549 cells.
Conclusion
The research provides insights into the effects of EGCG on proliferation and migratory inhibition, as well as highlighting its potential to induce apoptosis in lung cancer cells. These results support EGCG’s promise as a therapeutic agent in the treatment of lung cancer and further our understanding of the processes underlying its anticancer activities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical & Dental Sciences, College of Dentistry, Ajman University, Ajman, United Arab Emirates.
- Centre of Medical and Bio-allied Health Science Research, Ajman University, Ajman, United Arab Emirates.
- Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, Rome, Italy.
Förderung
- Ajman University Internal Research
Zitieren
APA
Khair, A. M. B., Maniangat Luke, A., Patnaik, R., & Testarelli, L. (2025). EGCG’s anticancer potential unveiled: triggering apoptosis in lung cancer cell lines through in vitro investigation. PeerJ, 13, e19135. https://doi.org/10.7717/peerj.19135
Vancouver
Khair AMB, Maniangat Luke A, Patnaik R, Testarelli L. EGCG’s anticancer potential unveiled: triggering apoptosis in lung cancer cell lines through in vitro investigation. PeerJ. 2025;13:e19135. doi:10.7717/peerj.19135
BibTeX
@article{Khair2025,
author = {Khair, Al Moutassem Billah and Maniangat Luke, Alexander and Patnaik, Rajashree and Testarelli, Luca},
title = {EGCG’s anticancer potential unveiled: triggering apoptosis in lung cancer cell lines through in vitro investigation},
journal = {PeerJ},
year = {2025},
volume = {13},
pages = {e19135},
doi = {10.7717/peerj.19135}
}
EUVIMED